Publication:
Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat

dc.contributor.authorJ. Tarningen_US
dc.contributor.authorN. Lindegardhen_US
dc.contributor.authorS. Sandbergen_US
dc.contributor.authorN. J.P. Dayen_US
dc.contributor.authorN. J. Whiteen_US
dc.contributor.authorM. Ashtonen_US
dc.contributor.otherGoteborg University, Sahlgrenska Academyen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChurchill Hospitalen_US
dc.date.accessioned2018-07-12T02:51:55Z
dc.date.available2018-07-12T02:51:55Z
dc.date.issued2008-01-01en_US
dc.description.abstractThis study aimed to evaluate the pharmacokinetic properties of pipera-quine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration. Male Sprague - Dawley rats were administered piperaquine as an emulsion orally or as a short-term intravenous infusion. Venous blood for pharmacokinetic evaluation was frequently withdrawn up to 90 h after dose. Urine, bile and faeces were collected after an infusion in rats kept in metabolic cages or in anesthetized rats. Pharmacokinetic characterization was done by compartmental modeling and non-compartmental analysis using WinNonlin. Piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after intravenous administration. The pharmacokinetics of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life. Piperaquine displayed a low biliary clearance and less than 1% of the total dose was recovered in urine. The absolute oral bioavailability was approximately 50%. The main metabolite after intravenous administration of piperaquine was a carboxylic acid product identical to that reported in humans. The similarity with results in humans indicates the rat to be a suitable species for nonclinical in vivo piperaquine studies. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association.en_US
dc.identifier.citationJournal of Pharmaceutical Sciences. Vol.97, No.8 (2008), 3400-3410en_US
dc.identifier.doi10.1002/jps.21226en_US
dc.identifier.issn15206017en_US
dc.identifier.issn00223549en_US
dc.identifier.other2-s2.0-52449086887en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/19884
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=52449086887&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the raten_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=52449086887&origin=inwarden_US

Files

Collections